COPD
GSK/Theravance lung drug bags CHMP approval
February 21, 2014Sales and Marketing CHMP, COPD, GSK, Theravance, anoro
The CHMP has given its backing to GlaxoSmithKline and partner Theravance’s new chronic obstructive pulmonary disease medicine Anoro. The treatment …
GSK banks on bioelectronics with new fund
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bioelectronics, COPD, GSK, asthma, diabetes
GSK has established a $50 million venture capital fund to invest in the emerging field of bioelectronics. Described as one …
AstraZeneca to pay up to $1.2 billion for Pearl
June 10, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, pearl therapeutics
AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …
GSK submits UMEC monotherapy
April 29, 2013Sales and Marketing COPD, EMA, GSK, UMEC
GlaxoSmithKline has put its investigational once-daily medicine umeclidinium bromide (UMEC) up for scrutiny by European regulators for patients with chronic …
Roche bins Galapagos tie-up
March 12, 2013Sales and Marketing COPD, Galapagos, Roche
Roche has ended its three-year old alliance with Belgian drug discovery specialist Galapagos because of a ‘strategic change’. The companies …
AstraZeneca signs respiratory deal
January 29, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, orexo, respiratory
AstraZeneca has signed a research deal with Swedish pharma company Orexo centred around the development of respiratory disease treatments. For …
EU submission for GSK and Theravance COPD drug
January 11, 2013Sales and Marketing COPD, GSK, Theravance, UMEC/VI
GlaxoSmithKline and Theravance have submitted their chronic obstructive pulmonary disease (COPD) drug UMEC/VI to European regulators. The application follows the …
Eisai and Novartis part ways
January 8, 2013Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva
Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …
Seebri Breezhaler approved in Europe
October 4, 2012Sales and Marketing COPD, Novartis, Relvar, Seebri Breezhaler, Tudorza
Novartis has been given approval in Europe for its Seebri Breezhaler to be used as maintenance treatment for chronic obstructive …
Novartis cheered by COPD trial results
September 3, 2012Research and Development COPD, ERS, Novartis
One of Novartis’ experimental respiratory drugs has proved superior in a late-stage trial to Boehringer Ingelheim and Pfizer’s existing brand …
Boehringer posts strong financials
August 16, 2012Sales and Marketing AMNOG, Boehringer, COPD, Spiriva
Boehringer Ingelheim has seen steady growth in the first half of 2012, but warns that the next six months may …
FDA approves Forest’s COPD drug
July 25, 2012Sales and Marketing COPD, FDA, Forest, Tudorza Pressair
US regulators have approved Forest Laboratories’ new chronic obstructive pulmonary disease (COPD) drug. Tudorza Pressair (aclidinium bromide) has been given …
GSK and Theravance post COPD pill data
July 2, 2012Research and Development, Sales and Marketing COPD, GSK, LABA, LAMA, Theravance
GSK and partner Theravance have released new data for its combination COPD drug. Results from four late-stage trials suggest that …
PMCPA reprimands Chiesi for multiple breaches
June 18, 2012Sales and Marketing COPD, Chiesi, GSK, PMCPA, code
Chiesi has been publicly reprimanded by the PMCPA part for promoting its asthma drug Fostair off-label. The embarrassing slapdown from …
Boehringer seeks NHS partners for COPD campaign
June 1, 2012Medical Communications, Sales and Marketing Boehringer, COPD, disease awareness campaign
Boehringer is seeking NHS partners for its COPD campaign: ‘Know it. Check it. Treat it.’ The campaign aims to raise …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
